Last edition
News about Clinical Trials
Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer
Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.
Clinical Trials | 30/07/2026 | By News Bureau
ProMIS Neurosciences Reports Positive Interim Phase 1b Results for Alzheimer's Therapy PMN310
ProMIS Neurosciences has reported positive six-month interim data from its Phase 1b PRECISE-AD trial, with PMN310 demonstrating a favourable safety profile, no ARIA-E cases and encouraging biomarker trends in patients with Alzheimer's disease.
Clinical Trials | 30/07/2026 | By News Bureau
Estrella Doses First Patient in EB103 Dose-Expansion Trial for Relapsed/Refractory B-Cell NHL
Estrella Immunopharma advances its STARLIGHT-1 Phase I/II trial with the first patient dosed in the EB103 dose-expansion cohort, building on promising early efficacy in relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Clinical Trials | 28/07/2026 | By News Bureau
Ultomiris Misses Phase 3 Endpoint in Post-Transplant TMA Trial
AstraZeneca shares a phase 3 update on Ultomiris for Haematopoietic Stem Cell Transplant (HSCT)-TMA, showing a trend toward clinical benefit in adults and adolescents as regulatory discussions continue.
Clinical Trials | 28/07/2026 | By News Bureau
AstraZeneca's investigational antibody-drug conjugate Sone-Ve demonstrated a significant overall survival benefit in the Phase 3 CLARITY-Gastric01 trial, marking a milestone in the development of targeted therapies for CLDN18.2-positive advanced gastric cancer.
Clinical Trials | 28/07/2026 | By News Bureau
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026
Insilico Medicine will present phase 1 data for Artificial Intelligence (AI)-designed pan-TEAD inhibitor ISM6331 at ESMO 2026 in mesothelioma and advanced solid tumors.
Clinical Trials | 28/07/2026 | By News Bureau
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Clinical Trials | 27/07/2026 | By News Bureau
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials. The company plans to submit a Biologics License Application (BLA) for retatrutide to the US Food and Drug Administration (FDA) in Q1 2027.
Clinical Trials | 25/07/2026 | By News Bureau
Healx Doses First Patient in Phase 1/2 Trial of AI-Discovered Therapy for Relapsed Osteosarcoma
Healx has dosed the first patient in its Phase 1/2 trial of AI-developed investigational therapy HLX-4310, marking a milestone in the development of novel treatments aimed at preventing metastatic recurrence in osteosarcoma and other rare cancers.
Clinical Trials | 24/07/2026 | By News Bureau
Argo Biopharma Doses First Patient in Phase 1 siRNA Trial
Argo Biopharma has dosed the first participant in the phase I trial of BW-41012, its Factor XI-targeting siRNA therapy for preventing thromboembolic diseases.
Clinical Trials | 22/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy